Ammonium chloride, also known as NH4Cl, is a widely used compound in the medical field. It is typically used as a buffer, to neutralize acidity in a solution, and as an electrolyte in medical solutions. It is also used in pharmaceuticals, as a preservative and as a stabilizer. Despite its widespread use, the potential of NH4Cl has yet to be fully explored. This article will explore the potential of NH4Cl, looking at its possible applications in medical treatments and other uses.
NH4Cl is a white, crystalline salt, with a molecular weight of 53.49 g/mol and a density of 1.527 g/cm3. It is highly soluble in water, with a solubility of 1.6 g/100 ml, and is also soluble in alcohols and other organic solvents. It is a weak acid, with a pKa of 9.25, and is readily hydrolyzed in water. It is also hygroscopic, meaning it absorbs moisture from the air.
NH4Cl is used in the medical field for a variety of purposes. It is used as a buffer, to neutralize acidity in a solution, and as an electrolyte in medical solutions. It is also used in pharmaceuticals, as a preservative and as a stabilizer. It is also used in the treatment of certain medical conditions, such as hypokalemia, hyperkalemia, and metabolic acidosis.
Despite its widespread use, the potential of NH4Cl has yet to be fully explored. Research has shown that NH4Cl has potential applications in the medical field, such as in the treatment of cancer, as a wound healing agent, and as an anti-inflammatory agent.
Research has shown that NH4Cl may have potential applications in the treatment of cancer. In one study, NH4Cl was found to inhibit the growth of human breast cancer cells in vitro. In another study, NH4Cl was found to inhibit the growth of human liver cancer cells in vitro. The mechanism of action is not yet clear, but it is thought to involve the inhibition of cell proliferation and the induction of apoptosis.
NH4Cl has also been studied for its potential use as a wound healing agent. In one study, NH4Cl was found to improve wound healing in animal models. The mechanism of action is not yet clear, but it is thought to involve the stimulation of collagen synthesis and the promotion of angiogenesis.
NH4Cl has also been studied for its potential use as an anti-inflammatory agent. In one study, NH4Cl was found to reduce inflammation in animal models. The mechanism of action is not yet clear, but it is thought to involve the inhibition of pro-inflammatory cytokines.
NH4Cl is a widely used compound in the medical field, used as a buffer, electrolyte, preservative, and stabilizer. Despite its widespread use, the potential of NH4Cl has yet to be fully explored. Research has shown that NH4Cl may have potential applications in the medical field, such as in the treatment of cancer, as a wound healing agent, and as an anti-inflammatory agent. Further research is needed to explore the potential of NH4Cl in these and other applications.
1.
According to the CAPTIVATE Study, fixed-duration ibrutinib plus venetoclax may be beneficial for patients with high-risk chronic lymphocytic leukemia.
2.
Scientists develop novel adjuvant delivery system to enhance cancer vaccine effectiveness
3.
Vepdegestrant Earns FDA Nod for ESR1-Mutated Breast Cancer
4.
According to a study, taking part in a clinical trial for cancer may not actually increase survival.
5.
A new blood test greatly increases the ability to detect cancer.
1.
Cancer Memory: A Persistent Threat to Tumor Recurrence and Metastasis
2.
Unraveling the Mysteries of Hematocrit: How It Impacts Your Health
3.
The Transformative Power of Genomics in the Diagnosis and Management of Rare Cancers
4.
Omega-3 Fatty Acids as Molecular Adjuvants Against Chemoresistance in Breast Cancer
5.
Surprising Symptoms of Prostate Cancer: What You Need to Know
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Navigating the Complexities of Ph Negative ALL - Part X
2.
Efficient Management of First line ALK-rearranged NSCLC - Part III
3.
What Therapy Would Yield the Best Outcomes In Patients with R/R B-cell ALL?
4.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part IV
5.
Updates on Standard V/S High Risk Myeloma Treatment- The Next Part
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation